STAT

Opinion: Advancing AI in health care: It’s all about trust

In drug trials, success in Phase 1 is no guarantee of success in Phase 3. In the current mania for AI and deep learning, a proof of concept is taken…

Three years ago, artificial intelligence pioneer Geoffrey Hinton said, “We should stop training radiologists now. It’s just completely obvious that within five years, deep learning is going to do better than radiologists.”

Today, hundreds of startup companies around the world are trying to apply deep learning to radiology. Yet the number of radiologists who have been replaced by AI is approximately zero. (In fact, there is a worldwide shortage of them.)

At least for the short term, that number is likely to remain unchanged. Radiology has proven harder to automate than Hinton — and many others — imagined. For medicine in general, this is no less true. There are many proofs of concept, such as from chest X-rays, but.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks